MGMT inhibition by disulfiram sensitizes ER+ breast cancer cells to temozolomide and cyclophosphamide

Authors

Santhi Konduri, Aurora Research Institute, Advocate Aurora HealthFollow
Deborah Donohoe, Advocate Aurora HealthFollow
Alisher Holmuhamednov, Advocate Aurora Health
Tarun Jella, Advocate Aurora Health
George C. Bobustuc, Advocate Aurora HealthFollow

Recommended Citation

Konduri SD, Donohoe D, Holmuhamedov A, Jella T, Bobustuc, GC. MGMT inhibition by disulfiram sensitizes ER+ breast cancer cells to temozolomide and cyclophosphamide. Poster presented at: Aurora Scientific Day; May 2 5, 2016; Milwaukee, WI.

Affiliations

Aurora Research Institute

Presentation Notes

Poster presented at: Aurora Scientific Day; May 25, 2016; Milwaukee, WI.

Abstract

Conclusion: Our findings suggest that DSF as dual inhibitor of MGMT and ALDH significantly enhances the antitumor effect of alkylators as CP and TMZ in ER+ breast cancer.

Document Type

Poster